Description
Sigirma 420 mg contains Pertuzumab, a recombinant humanized monoclonal antibody that specifically targets the HER2 (human epidermal growth factor receptor 2) protein. It is administered via intravenous infusion under oncology supervision.
🔬 Mechanism of Action
Pertuzumab binds to a distinct region (subdomain II) of the HER2 receptor. As a result, it prevents HER2 from pairing (dimerizing) with other HER family receptors, which is essential for tumor growth signaling. When combined with trastuzumab, it provides dual HER2 blockade, enhancing anti-tumor activity.
💊 Indications
Sigirma 420 mg is indicated for:
- HER2-positive metastatic breast cancer
- Neoadjuvant treatment of HER2-positive early breast cancer
- Adjuvant treatment of HER2-positive early breast cancer
It is typically used in combination with trastuzumab and chemotherapy agents as part of standard treatment regimens.
📌 Key Features of Sigirma 420 mg
- Strength: 420 mg
- Dosage Form: Intravenous infusion
- Therapeutic Class: Anti-HER2 Monoclonal Antibody
- Administration: IV infusion in a hospital or oncology setting
- Monitoring: Cardiac function monitoring (e.g., LVEF assessment) required during treatment
⚕️ Benefits of Pertuzumab
- Dual HER2 pathway inhibition (when combined with trastuzumab)
- Improves progression-free and overall survival
- Enhances response rates in early and metastatic settings
- Standard of care in HER2-positive breast cancer therapy
⚠️ Precautions
- Risk of infusion-related reactions
- Potential cardiotoxicity — regular cardiac monitoring required
- Not recommended during pregnancy
- Use strictly under oncologist supervision
Sigirma 420 mg (Pertuzumab Injection) provides an advanced targeted therapy option for HER2-positive breast cancer, supporting improved clinical outcomes through effective HER2 pathway inhibition when used under specialized medical care.
